EX-VIVO TREATMENT OF DONOR BONE MARROW WITH ANTI-T-CELL IMMUNOTOXINS FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE

A. H. Filipovich, R. J. Youle, D. M. Neville, D. A. Vallera, R. R. Quinones, J. H. Kersey

Research output: Contribution to journalArticle

135 Scopus citations

Abstract

Two patients undergoing marrow transplantation for acute lymphocytic leukaemia in third remission received from histocompatible siblings marrow pretreated with a mixture of three anti-T-cell immunotoxins, consisting of murine monoclonal antibodies covalently linked to ricin. This marrow processing effectively- eliminated functional T-cell responses while preserving the marrow precursors necessary for sustained haematoimmunopoietic engraftment. No post-transplant immunoprophylaxis was administered. Both patients showed prompt peripheral engraftment and were discharged from hospital within a month of transplantation. No toxic effects or graft-versus-host disease were apparent after the administration of immunotoxin-treated marrow. Ex-vivo immunotoxin pretreatment appears a safe and simple procedure which deserves further clinical testing as a sole method of graft-versus-host disease prophylaxis.

Original languageEnglish (US)
Pages (from-to)469-472
Number of pages4
JournalThe Lancet
Volume323
Issue number8375
DOIs
StatePublished - Mar 3 1984

Fingerprint Dive into the research topics of 'EX-VIVO TREATMENT OF DONOR BONE MARROW WITH ANTI-T-CELL IMMUNOTOXINS FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE'. Together they form a unique fingerprint.

  • Cite this